10:37 AM EST, 01/27/2025 (MT Newswires) -- ImmunityBio ( IBRX ) said Monday its marketing authorization application for Anktiva has been accepted for review by the European Medicines Agency.

The regulator has started evaluating the application for Anktiva in combination with Bacillus Calmette-Guerin to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors, the firm said.

Price: 3.25, Change: +0.08, Percent Change: +2.37